43 results on '"McClure, Myra O."'
Search Results
2. Ubiquitin-dependent virus particle budding without viral protein ubiquitination.
- Author
-
Zhadina, Maria, McClure, Myra O., Johnson, Marc C., and Bieniasz, Paul D.
- Subjects
- *
UBIQUITIN , *CELL membranes , *AMINO acid sequence , *LIGASES , *VIRAL proteins - Abstract
An essential step in the release of an extracellular enveloped virus particle is a budding event that ultimately separates virion and host cell membranes. For many enveloped viruses, membrane fission requires the recruitment of the class E vacuolar protein sorting (VPS) machinery by short, virally encoded peptide se- quences termed "late-budding" or "L" domains. Some L-domain peptide sequences (e.g., PSAP) bind directly to components of class E VPS machinery, whereas others (e.g., PPxY) access it indirectly by recruiting ubiquitin ligases. Additionally, ubiquitin itself is known to be generally important for the fission of virion from cellular membranes, and because ubiquitination of cellular transmembrane proteins can signal the recruitment of class E machinery, a popular model is that deposition of ubiquitin on viral structural proteins mediates class E machinery recruitment. To test this model, we took advantage of a retroviral Gag protein from the prototypic foamy virus (PFV) that is almost devoid of ubiquitin acceptors, and we engineered it to generate extracellular virus-like particles in the complete absence of other viral proteins. Notably, we found that particle budding, induced by a class E VPS machinery-binding L domain (PSAP), proceeded efficiently in the absence of ubiquitin acceptors in PFV Gag. Moreover, when particle release was engineered to be dependent on a viral PPXV motif, the requirement for a catalytically active ubiquitin ligase was maintained, irrespective of the presence or absence of ubiquitin acceptor sites in PFV Gag. Thus, in this model system, ubiquitin conjugation to transacting factors, not viral proteins, appears critical for ubiquitin-dependent enveloped viral particle release. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
3. High prevalence of macrolide resistant Treponema pallidum strains in a London centre.
- Author
-
Tipple, Craig, McClure, Myra O., and Taylor, Graham P.
- Subjects
- *
MACROLIDE antibiotics , *TREPONEMA pallidum , *GAY men's sexual behavior , *GENETIC mutation , *BLOOD testing - Abstract
Objectives: Macrolide resistant Treponema pallidum strains, caused by mutations in the 23S ribosomal RNA (23S rRNA) gene, are widespread and increasingly prevalent. The authors aimed to establish the strain types of T pallidum isolated from patients in a London sexual health centre and to determine the frequency of macrolide resistance.Methods: T pallidum DNA from blood and ulcer samples were subjected to strain typing and mutation analysis using previously described methods.Results: 18 samples were tested and a 23S rRNA point mutation conferring macrolide resistance was found in 66.6%. All resistant strains were collected from men who have sex with men and both the A2058G and the A2059G mutations were found. Two strain types were identified (14d/g and 14d/f); the predominant strain type was 14d/g and an association was noted between tp0548 type g and macrolide resistance.Conclusions: High levels of T pallidum macrolide resistance are present in London, UK, and this has clear implications for national treatment guidelines. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
4. Characterization of Rare Spontaneous Human Immunodeficiency Virus Viral Controllers Attending a National United Kingdom Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays.
- Author
-
Khan, Maryam, Bradshaw, Daniel, Brown, Colin S, Haddow, Jana, Patel, Poorvi, Tosswill, Jennifer H C, Pollock, Katrina, Elliott, Tamara, Wang, Xinzhu, Alagaratnam, Jasmini, Mora-Peris, Borja, Kaye, Steve, McClure, Myra O, Muir, David, Randell, Paul, Taylor, Graham P, and Fidler, Sarah J
- Abstract
Background We report outcomes and novel characterization of a unique cohort of 42 individuals with persistently indeterminate human immunodeficiency virus (HIV) status, the majority of whom are HIV viral controllers. Methods Eligible individuals had indeterminate or positive HIV serology, but persistently undetectable HIV ribonucleic acid (RNA) by commercial assays and were not taking antiretroviral therapy (ART). Routine investigations included HIV Western blot, HIV viral load, qualitative HIV-1 deoxyribonucleic acid (DNA), coinfection screen, and T-cell quantification. Research assays included T-cell activation, ART measurement, single-copy assays detecting HIV-1 RNA and DNA, and plasma cytokine quantification. Human immunodeficiency virus seropositivity was defined as ≥3 bands on Western blot; molecular positivity was defined as detection of HIV RNA or DNA. Results Human immunodeficiency virus infection was excluded in 10 of 42 referrals, remained unconfirmed in 2 of 42, and was confirmed in 30 of 42, who were identified as HIV elite controllers (ECs), normal CD4 T-cell counts (median 820/mL, range 805–1336), and normal CD4/CD8 ratio (median 1.8, range 1.2–1.9). Elite controllers had a median duration of elite control of 6 years (interquartile range = 4–14). Antiretroviral therapy was undetected in all 23 subjects tested. Two distinct categories of ECs were identified: molecular positive (n = 20) and molecular negative (n = 10). Conclusions Human immunodeficiency virus status was resolved for 95% of referrals with the majority diagnosed as EC. The clinical significance of the 2 molecular categories among ECs requires further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Origin of HIV.
- Author
-
McClure, Myra O. and Schulz, Thomas F.
- Subjects
- *
HIV , *LENTIVIRUSES , *AIDS - Abstract
Discusses the theories of the origin of HIV. Classification of HIV-I and HIV-II as lentiviruses; Speculations on the emergence of AIDS from monkeys; Effect of a recombination of several retrovirus on the evolution of HIV.
- Published
- 1989
- Full Text
- View/download PDF
6. Chlamydial Pgp3 Seropositivity and Population-Attributable Fraction Among Women With Tubal Factor Infertility.
- Author
-
Anyalechi, Gloria E., Hong, Jaeyoung, Kirkcaldy, Robert D., Wiesenfeld, Harold C., Horner, Paddy, Wills, Gillian S., McClure, Myra O., Hammond, Karen R., Haggerty, Catherine L., Kissin, Dmitry M., Hook III, Edward W., Steinkampf, Michael P., Bernstein, Kyle, Geisler, William M., and Hook, Edward W 3rd
- Subjects
- *
CHLAMYDIA infection diagnosis , *ENDOMETRIOSIS , *BACTERIAL antibodies , *CASE-control method , *INFERTILITY , *RESEARCH funding , *CHLAMYDIA trachomatis , *CHLAMYDIA infections , *DISEASE complications - Abstract
Background: Chlamydial infection is associated with tubal factor infertility (TFI); however, assessment of prior chlamydial infection and TFI is imperfect. We previously evaluated a combination of serological assays for association with TFI. We now describe the chlamydial contribution to TFI using a newer Chlamydia trachomatis Pgp3-enhanced serological (Pgp3) assay.Methods: In our case-control study of women 19 to 42 years old with hysterosalpingogram-diagnosed TFI (cases) and non-TFI (controls) in 2 US infertility clinics, we assessed possible associations and effect modifiers between Pgp3 seropositivity and TFI using adjusted odds ratios with 95% confidence intervals (CIs) stratified by race. We then estimated the adjusted chlamydia population-attributable fraction with 95% CI of TFI.Results: All Black (n = 107) and 618 of 620 non-Black women had Pgp3 results. Pgp3 seropositivity was 25.9% (95% CI, 19.3%-33.8%) for non-Black cases, 15.2% (95% CI, 12.3%-18.7%) for non-Black controls, 66.0% (95% CI, 51.7%-77.8%) for Black cases, and 71.7% (95% CI, 59.2%-81.5%) for Black controls. Among 476 non-Black women without endometriosis (n = 476), Pgp3 was associated with TFI (adjusted odds ratio, 2.6 [95% CI, 1.5-4.4]), adjusting for clinic, age, and income; chlamydia TFI-adjusted population-attributable fraction was 19.8% (95% CI, 7.7%-32.2%) in these women. Pgp3 positivity was not associated with TFI among non-Black women with endometriosis or among Black women (regardless of endometriosis).Conclusions: Among non-Black infertile women without endometriosis in these clinics, 20% of TFI was attributed to chlamydia. Better biomarkers are needed to estimate chlamydia TFI PAF, especially in Black women. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study.
- Author
-
Claudiani, Simone, Parker, Eleanor L., Milojkovic, Dragana, Rosadas, Carolina, Khan, Afzal, Katsanovskaja, Ksenia, Marchesin, Federica, Khan, Maryam, Tedder, Richard S., Innes, Andrew J., McClure, Myra O., and Apperley, Jane F.
- Subjects
- *
SARS-CoV-2 , *CHRONIC myeloid leukemia , *CONVALESCENT plasma - Abstract
The immune impairment related to some haematological malignancies and their treatments is considered responsible for the more severe COVID-19 [[1]] and the lower response rate to anti-SARS-CoV-2 vaccines in these patients [[2], [4]]. A total of 481 serological tests (Supplementary Figure 1) were performed over 9 months on 312 CML patients and we found 35 patients (11.2%) to be seropositive, of whom 23 (65.7%) recalled COVID-19 symptoms in the previous months and 12 (34.3%) were asymptomatic. Anti-SARS-CoV-2 seroprevalence, COVID-19 symptoms and persistence of natural anti-RBD antibodies in CML patients. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
8. Durable humoral responses after the second anti‐SARS‐CoV‐2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
- Author
-
Claudiani, Simone, Apperley, Jane F., Parker, Eleanor L., Marchesin, Federica, Katsanovskaja, Ksenia, Palanicawandar, Renuka, Innes, Andrew J., Tedder, Richard S., McClure, Myra O., and Milojkovic, Dragana
- Subjects
- *
DASATINIB , *CHRONIC myeloid leukemia , *PROTEIN-tyrosine kinase inhibitors , *CHRONIC leukemia , *SARS-CoV-2 , *HIV seroconversion - Abstract
At T3, 51/52 patients (98%) and 29/29 HS (100%) were seropositive, a finding that persisted at T4 (45/46 patients and 26/26 HS) with a single patient failing to seroconvert at any time. Keywords: CML; TKI; SARS-CoV-2; COVID-19; vaccines EN CML TKI SARS-CoV-2 COVID-19 vaccines e1 e4 4 03/30/22 20220401 NES 220401 The COVID-19 pandemic is a serious healthcare challenge, leading to more than 5 million deaths worldwide so far. At the time of their first vaccine dose, most patients ( I n i = 41, 76%) were receiving a 2 SP nd sp /3 SP rd sp -generation or newer TKI (which were dasatinib, nilotinib, bosutinib, ponatinib and asciminib in 21, 7, 5, 2 and 6 patients, respectively); 27 and 27 patients were in major molecular response and in deep molecular response, respectively. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
9. Xenotropic murine leukaemia virus-related virus (XMRV) does not cause chronic fatigue
- Author
-
Robinson, Mark J., Erlwein, Otto, and McClure, Myra O.
- Subjects
- *
MOUSE leukemia viruses , *CHRONIC fatigue syndrome , *PROSTATE cancer , *PATHOGENIC microorganisms , *BIOCHIPS , *MEDICAL technology - Abstract
The xenotropic murine leukaemia virus-related virus (XMRV), a gammaretrovirus, was discovered in prostate cancer tumours by Virochip technology in 2006. It was subsequently detected in chronic fatigue patients in 2009. The association between XMRV and chronic fatigue has proved to be controversial. No study has confirmed these findings and many have refuted them. Here, we present the evidence for our contention that XMRV is not a human pathogen. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
10. Failure to Detect the Novel Retrovirus XMRV in Chronic Fatigue Syndrome.
- Author
-
Erlwein, Otto, Kaye, Steve, McClure, Myra O., Weber, Jonathan, Wills, Gillian, Collier, David, Wessely, Simon, and Cleare, Anthony
- Subjects
- *
CHRONIC fatigue syndrome , *CANCER patients , *RETROVIRUSES , *RETROVIRUS diseases , *DNA , *LEUKEMIA , *PROSTATE cancer , *MEDICAL screening , *GLOBIN genes - Abstract
Background: In October 2009 it was reported that 68 of 101 patientswith chronic fatigue syndrome (CFS) in the US were infected with a novel gamma retrovirus, xenotropic murine leukaemia virus-related virus (XMRV), a virus previously linked to prostate cancer. This finding, if confirmed, would have a profound effect on the understanding and treatment of an incapacitating disease affecting millions worldwide. We have investigated CFS sufferers in the UK to determine if they are carriers of XMRV. Methodology: Patients in our CFS cohort had undergone medical screening to exclude detectable organic illness and met the CDC criteria for CFS. DNA extracted from blood samples of 186 CFS patients were screened for XMRV provirus and for the closely related murine leukaemia virus by nested PCR using specific oligonucleotide primers. To control for the integrity of the DNA, the cellular beta-globin gene was amplified. Negative controls (water) and a positive control (XMRV infectious molecular clone DNA) were included. While the beta-globin gene was amplified in all 186 samples, neither XMRV nor MLV sequences were detected. Conclusion: XMRV or MLV sequences were not amplified from DNA originating from CFS patients in the UK. Although we found no evidence that XMRV is associated with CFS in the UK, this may be a result of population differences between North America and Europe regarding the general prevalence of XMRV infection, and might also explain the fact that two US groups found XMRV in prostate cancer tissue, while two European studies did not. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
11. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia
- Author
-
Mackie, Nicola, Dustan, Simon, McClure, Myra O., Weber, Jonathan N., and Clarke, John R.
- Subjects
- *
ANTIRETROVIRAL agents , *HIV , *DRUG resistance , *GENETIC mutation - Abstract
We modified the Abbott diagnostics HIV-1 Viroseq version 2 assay™ in order to detect the presence of HIV-1 drug resistance mutations in patients with viraemia below 1000 copies/ml of plasma.One hundred and forty-four patients with a detectable HIV-1 plasma viral load below 1000 copies/ml were selected and HIV-1 genetic analysis carried out using a modification of the Abbott Diagnostics Viroseq 2.0 assay™. The procedure differs from the standard protocol in that a nested PCR amplification step was introduced. The oligonucleotide primers for the first round of PCR were those supplied in the RT-PCR module of the kit. The nested PCR primers were primers A and H taken from the sequencing module. One hundred and twenty-eight out of 144 (89%) plasma samples with an HIV-1 viral load of less than 1000 copies/ml (ranging from 54 to 992 copies) were successfully sequenced. HIV-1 genotypes were obtained from 68 out of 81 (84%) samples with a viral load of greater than 50 but less than 300 copies/ml and 60/63 (95%) of samples with a viral load of greater than 300 but less than 1000 copies/ml. Serial dilution of a sample with a high viral load did not affect the detection of resistance mutations. Multiple sequencing of samples with low viral load did not result in detection of additional mutations, although, in one sample the K103N mutation was detected in 3/6 replicates while wild-type was detected in 2/6 and a mixture of wild-type/mutant in 1/6. Samples from patients infected with both clade B and non-B clades of HIV-1 could be genotyped at low copy number. Modification of the Abbott Viroseq assay allows reproducible sequencing of the HIV-1 genome from patients with low, but detectable, plasma virus burden. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
12. Inhibition of Human Immunodeficiency Virus Type 1 Replication in Primary Macrophages by Using Tat- or CCR5-Specific Small Interfering RNAs Expressed from a Lentivirus Vector.
- Author
-
Lee, Ming-Ta M., Coburn, Glen A., McClure, Myra O., and Cullen, Bryan R.
- Subjects
- *
HIV , *VIRAL replication , *GENETIC vectors - Abstract
Although several groups have demonstrated that RNA interference, induced by transfection of small interfering RNA (siRNA) duplexes, can protect cells against a viral challenge in culture, this protection is transient. Here, we describe lentivirus expression vectors that can stably express siRNAs at levels sufficient to block virus replication. We have used these vectors to stably express siRNAs specific for the essential human immunodeficiency virus type 1 (HIV-1) Tat transcription factor or specific for a cellular coreceptor, CCR5, that is required for infection by the majority of primary HIV-1 isolates. These lentivirus vectors are shown to protect cells, including primary macrophages, against HIV-1 infection in culture by inducing selective degradation of their target mRNA species. These data suggest that it should be possible to block the expression of specific viral or cellular genes in vivo by using viral vectors to stably express the appropriate siRNAs. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
13. The Association Between Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Post-COVID-19 Syndrome in Healthcare Workers.
- Author
-
Pereira, Christopher, Harris, Benjamin H L, Giovannantonio, Matteo Di, Rosadas, Carolina, Short, Charlotte-Eve, Quinlan, Rachael, Sureda-Vives, Macià, Fernandez, Natalia, Day-Weber, Isaac, Khan, Maryam, Marchesin, Federica, Katsanovskaja, Ksenia, Parker, Eleanor, Taylor, Graham P, Tedder, Richard S, McClure, Myra O, Dani, Melanie, Fertleman, Michael, and Di Giovannantonio, Matteo
- Subjects
- *
MEDICAL personnel , *COVID-19 , *COVID-19 pandemic , *ANTIBODY formation , *SARS-CoV-2 - Abstract
It is currently unknown how post-COVID-19 syndrome (PCS) may affect those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This longitudinal study includes healthcare staff who tested positive for SARS-CoV-2 between March and April 2020, with follow-up of their antibody titers and symptoms. More than half (21 of 38) had PCS after 7-8 months. There was no statistically significant difference between initial reverse-transcription polymerase chain reaction titers or serial antibody levels between those who did and those who did not develop PCS. This study highlights the relative commonality of PCS in healthcare workers and this should be considered in vaccination scheduling and workforce planning to allow adequate frontline staffing numbers. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Severe Acute Respiratory Syndrome Coronavirus-2 Infections in Critical Care Staff: Beware the Risks Beyond the Bedside.
- Author
-
El Bouzidi, Kate, Pirani, Tasneem, Rosadas, Carolina, Ijaz, Samreen, Pearn, Matthew, Chaudhry, Shehnila, Patel, Sameer, Sureda-Vives, Macià, Fernandez, Natalia, Khan, Maryam, Cherepanov, Peter, McClure, Myra O., Tedder, Richard S., and Zuckerman, Mark
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *CRITICAL care medicine , *ANTIBODY titer , *PERSONAL protective equipment - Abstract
OBJECTIVES: Critical care workers were considered to be at high risk of severe acute respiratory syndrome coronavirus-2 infection from patients during the first wave of the pandemic. Staff symptoms, previous swab testing, and antibody prevalence were correlated with patient admissions to investigate this assumption. DESIGN: Cross-sectional study. SETTING: A large critical care department in a tertiary-care teaching hospital in London, United Kingdom. SUBJECTS: Staff working in critical care. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Participants completed a questionnaire and provided a serum sample for severe acute respiratory syndrome coronavirus-2 antibody testing over a 3-day period in April 2020. We compared the timing of symptoms in staff to the coronavirus disease 2019 patient admissions to critical care. We also identified factors associated with antibody detection. Of 625 staff, 384 (61.4%) reported previous symptoms and 124 (19.8%) had sent a swab for testing. Severe acute respiratory syndrome coronavirus-2 infection had been confirmed in 37 of those swabbed (29.8%). Overall, 21% (131/625) had detectable severe acute respiratory syndrome coronavirus-2 antibody, of whom 9.9% (13/131) had been asymptomatic. The peak onset of symptoms among staff occurred 2 weeks before the peak in coronavirus disease 2019 patient admissions. Staff who worked in multiple departments across the hospital were more likely to be seropositive. Staff with a symptomatic household contact were also more likely to be seropositive at 31.3%, compared with 16.2% in those without (p < 0.0001). CONCLUSIONS: Staff who developed coronavirus disease 2019 were less likely to have caught it from their patients in critical care. Other staff, other areas of the hospital, and the wider community are more likely sources of infection. These findings indicate that personal protective equipment was effective at preventing transmission from patients. However, staff also need to maintain protective measures away from the bedside. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Rehabilitation Facility: Evolution of the Presence of Nasopharyngeal SARS-CoV-2 and Serological Antibody Responses.
- Author
-
Harris, Benjamin H L, Zuhair, Mohamed, Giovannantonio, Matteo Di, Rosadas, Carolina, Khan, Maryam, Short, Charlotte-Eve, Thaventhiran, Thilipan, Quinlan, Rachael, Taylor, Andrew, Calvez, Ronan, Taylor, Graham P, Tedder, Richard S, McClure, Myra O, Fertleman, Michael, and Di Giovannantonio, Matteo
- Subjects
- *
COVID-19 , *SARS-CoV-2 , *ANTIBODY formation , *POLYMERASE chain reaction - Abstract
At the start of the UK coronavirus disease 2019 epidemic, this rare point prevalence study revealed that one-third of patients (15 of 45) in a London inpatient rehabilitation unit were found to be infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) but asymptomatic. We report on 8 patients in detail, including their clinical stability, the evolution of their nasopharyngeal viral reverse-transcription polymerase chain reaction (RT-PCR) burden, and their antibody levels over time, revealing the infection dynamics by RT-PCR and serology during the acute phase. Notably, a novel serological test for antibodies against the receptor binding domain of SARS-CoV-2 showed that 100% of our asymptomatic cohort remained seropositive 3-6 weeks after diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Sera selected from national STI surveillance system shows Chlamydia trachomatis PgP3 antibody correlates with time since infection and number of previous infections.
- Author
-
Blomquist, Paula B., Mighelsen, Stephanie J., Wills, Gillian, McClure, Eleanor, Ades, Anthony E., Kounali, Daphne, Dunbar, J. Kevin, McClure, Myra O., Soldan, Kate, Woodhall, Sarah C., and Horner, Patrick
- Subjects
- *
TRACHOMA , *ANTIBODY diversity , *CHLAMYDIA , *CHLAMYDIACEAE , *SEXUALLY transmitted diseases - Abstract
Background: Seroprevalence surveys of Chlamydia trachomatis (CT) antibodies are promising for estimating age-specific CT cumulative incidence, however accurate estimates require improved understanding of antibody response to CT infection. Methods: We used GUMCAD, England’s national sexually transmitted infection (STI) surveillance system, to select sera taken from female STI clinic attendees on the day of or after a chlamydia diagnosis. Serum specimens were collected from laboratories and tested anonymously on an indirect and a double-antigen ELISA, both of which are based on the CT-specific Pgp3 antigen. We used cross-sectional and longitudinal descriptive analyses to explore the relationship between seropositivity and a) cumulative number of chlamydia diagnoses and b) time since most recent chlamydia diagnosis. Results: 919 samples were obtained from visits when chlamydia was diagnosed and 812 during subsequent follow-up visits. Pgp3 seropositivity using the indirect ELISA increased from 57.1% (95% confidence interval: 53.2–60.7) on the day of a first-recorded chlamydia diagnosis to 89.6% (95%CI: 79.3–95.0) on the day of a third or higher documented diagnosis. With the double-antigen ELISA, the increase was from 61.1% (95%CI: 53.2–60.7) to 97.0% (95%CI: 88.5–99.3). Seropositivity decreased with time since CT diagnosis on only the indirect assay, to 49.3% (95%CI: 40.9–57.7) two or more years after a first diagnosis and 51.9% (95%CI: 33.2–70.0) after a repeat diagnosis. Conclusion: Seropositivity increased with cumulative number of infections, and decreased over time after diagnosis on the indirect ELISA, but not on the double-antigen ELISA. This is the first study to demonstrate the combined impact of number of chlamydia diagnoses, time since diagnosis, and specific ELISA on Pgp3 seropositivity. Our findings are being used to inform models estimating age-specific chlamydia incidence over time using serial population-representative serum sample collections, to enable accurate public health monitoring of chlamydia. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Chlamydia trachomatis Incidence Using Self-Reports and Serology by Gender, Age Period, and Sexual Behavior in a Birth Cohort.
- Author
-
Righarts, A. Antoinette, Morgan, Jane, Horner, Paddy J., Wills, Gillian S., McClure, Myra O., and Dickson, Nigel P.
- Subjects
- *
CHLAMYDIA infection prevention , *AGE distribution , *BACTERIAL antigens , *BACTERIAL proteins , *CHLAMYDIA infections , *CHLAMYDIA trachomatis , *HEALTH attitudes , *LONGITUDINAL method , *SELF-evaluation , *HUMAN sexuality , *SEX distribution , *UNSAFE sex , *DISEASE incidence , *SEXUAL partners , *PSYCHOLOGY - Abstract
Background: Although understanding chlamydia incidence assists prevention and control, analyses based on diagnosed infections may distort the findings. Therefore, we determined incidence and examined risks in a birth cohort based on self-reports and serology.Methods: Self-reported chlamydia and behavior data were collected from a cohort born in New Zealand in 1972/3 on several occasions to age 38 years. Sera drawn at ages 26, 32, and 38 years were tested for antibodies to Chlamydia trachomatis Pgp3 antigen using a recently developed assay, more sensitive in women (82.9%) than men (54.4%). Chlamydia incidence by age period (first coitus to age 26, 26-32, and 32-38 years) was calculated combining self-reports and serostatus and risk factors investigated by Poisson regression.Results: By age 38 years, 32.7% of women and 20.9% of men had seroconverted or self-reported a diagnosis. The highest incidence rate was to age 26, 32.7 and 18.4 years per 1000 person-years for women and men, respectively. Incidence rates increased substantially with increasing number of sexual partners. After adjusting age period incidence rates for partner numbers, a relationship with age was not detected until 32 to 38 years, and then only for women.Conclusions: Chlamydia was common in this cohort by age 38, despite the moderate incidence rates by age period. The strongest risk factor for incident infection was the number of sexual partners. Age, up to 32 years, was not an independent factor after accounting for partner numbers, and then only for women. Behavior is more important than age when considering prevention strategies. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
18. Chlamydia trachomatis Pgp3 Antibody Population Seroprevalence before and during an Era of Widespread Opportunistic Chlamydia Screening in England (1994-2012).
- Author
-
Woodhall, Sarah C., Wills, Gillian S., Horner, Patrick J., Craig, Rachel, Mindell, Jennifer S., Murphy, Gary, McClure, Myra O., Soldan, Kate, Nardone, Anthony, and Johnson, Anne M.
- Subjects
- *
CHLAMYDIA trachomatis , *SEROPREVALENCE , *OPPORTUNISTIC infections , *PUBLIC health , *HEALTH surveys , *DIAGNOSIS - Abstract
Background: Opportunistic chlamydia screening of <25 year-olds was nationally-implemented in England in 2008 but its impact on chlamydia transmission is poorly understood. We undertook a population-based seroprevalence study to explore the impact of screening on cumulative incidence of chlamydia, as measured by C.trachomatis-specific antibody. Methods: Anonymised sera from participants in the nationally-representative Health Surveys for England (HSE) were tested for C.trachomatis antibodies using two novel Pgp3 enzyme-linked immunosorbent assays (ELISAs) as a marker of past infection. Determinants of being seropositive were explored using logistic regression among 16–44 year-old women and men in 2010 and 2012 (years when sexual behaviour questions were included in the survey) (n = 1,402 women; 1,119 men). Seroprevalence trends among 16–24 year-old women (n = 3,361) were investigated over ten time points from 1994–2012. Results: In HSE2010/2012, Pgp3 seroprevalence among 16–44 year-olds was 24.4% (95%CI 22.0–27.1) in women and 13.9% (11.8–16.2) in men. Seroprevalence increased with age (up to 33.5% [27.5–40.2] in 30–34 year-old women, 18.7% [13.4–25.6] in 35–39 year-old men); years since first sex; number of lifetime sexual partners; and younger age at first sex. 76.7% of seropositive 16–24 year-olds had never been diagnosed with chlamydia. Among 16–24 year-old women, a non-significant decline in seroprevalence was observed from 2008–2012 (prevalence ratio per year: 0.94 [0.84–1.05]). Conclusion: Our application of Pgp3 ELISAs demonstrates a high lifetime risk of chlamydia infection among women and a large proportion of undiagnosed infections. A decrease in age-specific cumulative incidence following national implementation of opportunistic chlamydia screening has not yet been demonstrated. We propose these assays be used to assess impact of chlamydia control programmes. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. Chlamydia trachomatis Pgp3 Antibody Persists and Correlates with Self-Reported Infection and Behavioural Risks in a Blinded Cohort Study.
- Author
-
Horner, Patrick J., Wills, Gillian S., Righarts, Antoinette, Vieira, Sueli, Kounali, Daphne, Samuel, Dhanraj, Winston, Alan, Muir, David, Dickson, Nigel P., and McClure, Myra O.
- Subjects
- *
CHLAMYDIA trachomatis , *IMMUNOGLOBULINS , *SEROLOGY , *ENZYME-linked immunosorbent assay , *COMMUNICABLE diseases , *OPPORTUNISTIC infections - Abstract
Chlamydia trachomatis (Ct) serological studies in populations could help monitor changes in lifetime cumulative risk of infection. We developed a double-antigen sandwich ELISA based on the Ct-specific Pgp3 antigen, then tested blind stored sera from over 800 participants in a New Zealand birth cohort from Dunedin at ages 26, 32 and 38. The double-antigen sandwich ELISA was more sensitive than our previously characterised indirect Pgp3 ELISA. Pgp3 antibody was detected more often in women compared to men and correlated with increasing numbers of sexual partners, self-reported Ct, and younger age at sexual debut in both women and men. At age 26, 24.1% (99/411) of women were Pgp3 seropositive, as were 79.5% (35/44) of those reporting Ct infection; Pgp3 antibody persisted to age 38 in 96.5% (83/86). In men at age 26, the figures were 10.7% (47/442) and 25.0% (6/24), respectively, with high (83.9%) antibody persistence to age 38. At age 38, among those Pgp3 seropositive, 63.3% of women and 83.1% of men had not reported Ct infection. Thus, Ct-specific Pgp3 antibody was detected in most women reporting Ct infection and correlated with risk of infection in those who did not, with most infections remaining undetected. As this antibody persisted for at least twelve years in 96% of these women, serology could be used to evaluate Ct prevention programmes among women. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
20. The Rsb Phosphoregulatory Network Controls Availability of the Primary Sigma Factor in Chlamydia trachomatis and Influences the Kinetics of Growth and Development.
- Author
-
Thompson, Christopher C., Griffiths, Cherry, Nicod, Sophie S., Lowden, Nicole M., Wigneshweraraj, Sivaramesh, Fisher, Derek J., and McClure, Myra O.
- Subjects
- *
CHLAMYDIA trachomatis , *CHLAMYDIA , *PATHOGENIC microorganisms , *MICROORGANISMS , *BIPHASIC insulin , *PEPTIDE hormones - Abstract
Chlamydia trachomatis is an obligate intracellular human pathogen that exhibits stage-specific gene transcription throughout a biphasic developmental cycle. The mechanisms that control modulation in transcription and associated phenotypic changes are poorly understood. This study provides evidence that a switch-protein kinase regulatory network controls availability of σ66, the main sigma subunit for transcription in Chlamydia. In vitro analysis revealed that a putative switch-protein kinase regulator, RsbW, is capable of interacting directly with σ66, as well as phosphorylating its own antagonist, RsbV1, rendering it inactive. Conversely, the putative PP2C-like phosphatase domain of chlamydial RsbU was capable of reverting RsbV1 into its active state. Recent advances in genetic manipulation of Chlamydia were employed to inactivate rsbV1, as well as to increase the expression levels of rsbW or rsbV1, in vivo. Representative σ66-dependent gene transcription was repressed in the absence of rsbV1 or upon increased expression of RsbW, and increased upon elevated expression of RsbV1. These effects on housekeeping transcription were also correlated to several measures of growth and development. A model is proposed where the relative levels of active antagonist (RsbV1) and switch-protein anti-sigma factor (RsbW) control the availability of σ66 and subsequently act as a molecular 'throttle' for Chlamydia growth and development. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Obituary: Axel Rethwilm (1959–2014)
- Author
-
Berkhout, Ben, Bodem, Jochen, Erlwein, Otto, Herchenröder, Ottmar, Khan, Arifa S, Lever, Andrew ML, Lindemann, Dirk, Linial, Maxine L, Löchelt, Martin, McClure, Myra O, Scheller, Carsten, and Weiss, Robin A
- Published
- 2014
- Full Text
- View/download PDF
22. Effect of time since exposure to Chlamydia trachomatis on chlamydia antibody detection in women: a cross-sectional study.
- Author
-
Horner, Patrick J., Wills, Gillian S., Reynolds, Rosy, Johnson, Anne M., Muir, David A., Winston, Alan, Broadbent, Andrew J., Parker, David, and McClure, Myra O.
- Subjects
- *
CHLAMYDIA trachomatis , *GENITAL diseases , *SEXUALLY transmitted disease diagnosis , *WOMEN'S health , *CHLAMYDIA infections - Abstract
Objectives To investigate what factors influence the detection of Chlamydia trachomatis antibody following genital tract infection. Methods One hundred and sixty-four women with a previous history of C trachomatis infection contributed to an earlier report on the performance of chlamydia antibody ELISA assays. We undertook further analysis to explore how chlamydia antibody assay sensitivity changes with time since infection. Results Chlamydia antibody was detected in more women soon after the last detection of chlamydia at the lower genital tract than at later times. This holds true for all tests, but the Anilabsystems IgG EIA, Medac pELISA plus ELISA and the Savyon SeroCT-IgG ELISA were less sensitive than the pgp3 ELISA and the Anilabsystems microimmunofluorescence (MIF) assay at all time points except during current infection. Fall in seropositivity in women generally occurred in the early weeks and months following the last episode of chlamydia infection. There was no clear pattern of further reduction in seropositivity after 6 months. Multiple previous episodes were associated with increased seropositivity in the pgp3 assay (two or more vs one, OR 19, p<0.001) and other tests, but the effect was significantly smaller for the Anilabs, Medac and SeroCT MOMP peptide ELISAs, but not for the MIF assay. Conclusions Chlamydia antibody detection decreases with time since infection and this is most apparent in the first 6 months. In women who have had more than one infection, antibody remained detectable longer for all tests, but this was more marked for the pgp3 ELISA and MIF assay. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
23. C. trachomatis pgp3 Antibody Prevalence in Young Women in England, 1993–2010.
- Author
-
Horner, Paddy, Soldan, Kate, Vieira, Sueli M., Wills, Gillian S., Woodhall, Sarah C., Pebody, Richard, Nardone, Anthony, Stanford, Elaine, and McClure, Myra O.
- Subjects
- *
CHLAMYDIA , *IMMUNOGLOBULINS , *DISEASE prevalence , *YOUNG women , *WOMEN , *COMMUNICABLE diseases , *PUBLIC health , *SEXUALLY transmitted diseases - Abstract
Seroepidemiology of chlamydia can offer study opportunities and insights into cumulative risk of exposure that may contribute to monitoring the frequency of, and control of, genital chlamydia–the most commonly diagnosed STI in England. We undertook retrospective anonymous population-based cross-sectional surveys using an indirect IgG ELISA for chlamydia Pgp3 antibody. Sera from 4,732 women aged 17–24 years were tested. Samples were taken at 3-yearly intervals between 1993 and 2002, a period during which other data suggest chlamydia transmission may have been increasing, and from each year between 2007 and 2010. Seroprevalence increased in 17–24 year olds over time between 1993 and 2002. Between 2007 and 2010, age-standardised seroprevalence among 17–24 year olds decreased from 20% (95% CI: 17–23) to 15% (95%CI 12–17) (p = 0.0001). The biggest drop was among 20 to 21 year olds, where seroprevalence decreased from 21% in 2007 to 9% in 2010 (p = 0.002). These seroprevalence data reflect some known features of the epidemiology of chlamydia infection, and show that exposure to antibody-inducing chlamydia infection has declined in recent years. This decline was concurrent with increasing rates of screening for asymptomatic chlamydia. Serology should be explored further as a tool for evaluation of chlamydia control, including chlamydia screening programmes. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
24. Highly sensitive and specific detection of the SARS-CoV-2 Delta variant by double-mismatch allele-specific real time reverse transcription PCR.
- Author
-
Garson, Jeremy A., Badru, Samuel, Parker, Eleanor, Tedder, Richard S., and McClure, Myra O.
- Subjects
- *
SARS-CoV-2 , *DIAGNOSTIC use of polymerase chain reaction , *NUCLEOTIDE sequencing , *HEALTH policy , *MEDICAL screening - Abstract
• Allele-specific PCR for identification of the SARS-CoV-2 Delta variant is described. • The method is a simple, rapid and inexpensive alternative to genome sequencing. • Genotyping results by allele-specific PCR were entirely concordant with sequencing. • Sensitivity of allele-specific PCR matched that of the SARS-CoV-2 diagnostic PCR. • Samples with insufficient virus for sequencing were successfully genotyped. The highly transmissible Delta variant of SARS-CoV-2 (B.1.617.2), first identified in India, is currently replacing pre-existing variants in many parts of the world. To help guide public health policies it is important to monitor efficiently its spread. Genome sequencing is the gold standard for identification of Delta, but is time-consuming, expensive, and unavailable in many regions. To develop and evaluate a rapid, simple and inexpensive alternative to sequencing for Delta identification. A double-mismatch allele-specific RT-PCR (DMAS-RT-PCR) was developed. The technique exploits allele-specific primers, targeting two spike gene mutations, L452R and T478K, within the same amplicon. The discriminatory power of each primer was enhanced by an additional mismatch located at the fourth nucleotide from the 3′ end. Specificity was assessed by testing well characterised cell culture-derived viral isolates and clinical samples, most of which had previously been fully sequenced. In all cases the results of viral genotyping by DMAS-RT-PCR were entirely concordant with the results of sequencing, and the assay was shown to discriminate reliably between the Delta variant and other variants (Alpha and Beta), and 'wild-type' SARS-CoV-2. Influenza A and RSV were non-reactive in the assay. The sensitivity of DMAS-RT-PCR matched that of the diagnostic SARS-CoV-2 RT-qPCR screening assay. Several samples that could not be sequenced due to insufficient virus were successfully genotyped by DMAS-RT-PCR. The method we describe would be simple to establish in any laboratory that can conduct PCR assays and should greatly facilitate monitoring of the spread of the Delta variant globally. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters.
- Author
-
Gall, Astrid, Kaye, Steve, Hué, Stéphane, Bonsall, David, Rance, Richard, Baillie, Gregory J., Fidler, Sarah J., Weber, Jonathan N., McClure, Myra O., and Kellam, Paul
- Subjects
- *
HIV infections , *THERAPEUTICS , *CROSS-sectional method , *SEROCONVERSION , *BIOMARKERS , *ANTIRETROVIRAL agents , *QUANTITATIVE research , *GENE amplification , *AMINO acid sequence , *AIDS , *COHORT analysis - Abstract
Background: Dynamic changes in Human Immunodeficiency Virus 1 (HIV-1) sequence diversity and divergence are associated with immune control during primary infection and progression to AIDS. Consensus sequencing or single genome amplification sequencing of the HIV-1 envelope (env) gene, in particular the variable (V) regions, is used as a marker for HIV-1 genome diversity, but population diversity is only minimally, or semi-quantitatively sampled using these methods. Results: Here we use second generation deep sequencing to determine inter-and intra-patient sequence heterogeneity and to quantify minor variants in a cohort of individuals either receiving or not receiving antiretroviral treatment following seroconversion; the SPARTAC trial. We show, through a cross-sectional study of sequence diversity of the env V3 in 30 antiretroviral-naive patients during primary infection that considerable population structure diversity exists, with some individuals exhibiting highly constrained plasma virus diversity. Diversity was independent of clinical markers (viral load, time from seroconversion, CD4 cell count) of infection. Serial sampling over 60 weeks of non-treated individuals that define three initially different diversity profiles showed that complex patterns of continuing HIV-1 sequence diversification and divergence could be readily detected. Evidence for minor sequence turnover, emergence of new variants and re-emergence of archived variants could be inferred from this analysis. Analysis of viral divergence over the same time period in patients who received short (12 weeks, ART12) or long course antiretroviral therapy (48 weeks, ART48) and a non-treated control group revealed that ART48 successfully suppressed viral divergence while ART12 did not have a significant effect. Conclusions: Deep sequencing is a sensitive and reliable method for investigating the diversity of the env V3 as an important component of HIV-1 genome diversity. Detailed insights into the complex early intra-patient dynamics of env V3 diversity and divergence were explored in antiretroviral-naïve recent seroconverters. Long course antiretroviral therapy, initiated soon after seroconversion and administered for 48 weeks, restricts HIV-1 divergence significantly. The effect of ART12 and ART48 on clinical markers of HIV infection and progression is currently investigated in the SPARTAC trial. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
26. Nef Decreases HIV-1 Sensitivity to Neutralizing Antibodies that Target the Membrane-proximal External Region of TMgp41.
- Author
-
J. Lai, Rachel P., Jin Yan, Heeney, Jonathan, McClure, Myra O., Göttlinger, Heinrich, Luban, Jeremy, and Pizzato, Massimo
- Abstract
Primate lentivirus nef is required for sustained virus replication in vivo and accelerated progression to AIDS. While exploring the mechanism by which Nef increases the infectivity of cell-free virions, we investigated a functional link between Nef and Env. Since we failed to detect an effect of Nef on the quantity of virion-associated Env, we searched for qualitative changes by examining whether Nef alters HIV-1 sensitivity to agents that target distinct features of Env. Nef conferred as much as 50- fold resistance to 2F5 and 4E10, two potent neutralizing monoclonal antibodies (nAbs) that target the membrane proximal external region (MPER) of TMgp41. In contrast, Nef had no effect on HIV-1 neutralization by MPER-specific nAb Z13e1, by the peptide inhibitor T20, nor by a panel of nAbs and other reagents targeting gp120. Resistance to neutralization by 2F5 and 4E10 was observed with Nef from a diverse range of HIV-1 and SIV isolates, as well as with HIV-1 virions bearing Env from CCR5- and CXCR4-tropic viruses, clade B and C viruses, or primary isolates. Functional analysis of a panel of Nef mutants revealed that this activity requires Nef myristoylation but that it is genetically separable from other Nef functions such as the ability to enhance virus infectivity and to downregulate CD4. Glycosylated-Gag from MoMLV substituted for Nef in conferring resistance to 2F5 and 4E10, indicating that this activity is conserved in a retrovirus that does not encode Nef. Given the reported membrane-dependence of MPER-recognition by 2F5 and 4E10, in contrast to the membrane-independence of Z13e1, the data here is consistent with a model in which Nef alters MPER recognition in the context of the virion membrane. Indeed, Nef and Glycosylated-Gag decreased the efficiency of virion capture by 2F5 and 4E10, but not by other nAbs. These studies demonstrate that Nef protects lentiviruses from one of the most broadly-acting classes of neutralizing antibodies. This newly discovered activity for Nef has important implications for anti-HIV-1 immunity and AIDS pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
27. Getting the measure of syphilis: qPCR to better understand early infection.
- Author
-
Tipple, Craig, Hanna, Mariam O. F., Hill, Samantha, Daniel, Jessica, Goldmeier, David, McClure, Myra O., and Taylor, Graham P.
- Subjects
- *
TREPONEMA pallidum , *LIPOPROTEINS , *SEXUALLY transmitted diseases , *HIV infections , *BACTEREMIA - Abstract
Objectives: Until recently, PCR had been used to detect but not quantify Treponema pallidum. To understand infection kinetics of this uncultivable organism, a real-time PCR assay was developed to quantify 47 kDa membrane lipoprotein gene DNA (tpp47).Methods: Assay specificity was determined against DNA from humans, skin organisms and sexually transmitted pathogens. tpp47 DNA (Nichols strain) was used to construct a standard curve for T pallidum quantification. Blood and ulcer samples were obtained from 99 patients being investigated or screened for syphilis and tpp47 was quantified.Results: The assay was specific, not cross-reactive with other organisms tested and sensitive, with a detection limit of a single copy of tpp47 DNA. For ulcer samples, the assay was 100% sensitive and 97.14% specific. Sensitivity fell to 34.1% for blood samples but specificity remained high (100%). tpp47 DNA was more commonly detected, and at a higher copy number, in blood of patients with secondary infection (sensitivity 57.89%) compared with primary infection. Quantity of tpp47 DNA was higher in primary infection ulcers, especially in HIV-1-positive patients, than in ulcers persisting into secondary disease.Conclusions: Quantifying T pallidum provides insight into syphilis infection kinetics: Ulcers of primary disease in HIV-1-positive patients are perhaps more infectious and the presence and load of T pallidum bacteraemia is variable, with a peak in the secondary stage. Quantitative PCR has the potential to map T pallidum infection and to highlight the impact of HIV on syphilis. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
28. DNA extraction columns contaminated with murine sequences.
- Author
-
Erlwein, Otto, Robinson, Mark J., Dustan, Simon, Weber, Jonathan, Kaye, Steve, and McClure, Myra O.
- Abstract
Sequences of the novel gammaretrovirus, xenotropic murine leukemia virus-related virus (XMRV) have been described in human prostate cancer tissue, although the amounts of DNA are low. Furthermore, XMRV sequences and polytropic (p) murine leukemia viruses (MLVs) have been reported in patients with chronic fatigue syndrome (CFS). In assessing the prevalence of XMRV in prostate cancer tissue samples we discovered that eluates from naïve DNA purification columns, when subjected to PCR with primers designed to detect genomic mouse DNA contamination, occasionally gave rise to amplification products. Further PCR analysis, using primers to detect XMRV, revealed sequences derived from XMRV and pMLVs from mouse and human DNA and DNA of unspecified origin. Thus, DNA purification columns can present problems when used to detect minute amounts of DNA targets by highly sensitive amplification techniques. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
29. Investigation into the Presence of and Serological Response to XMRV in CFS Patients.
- Author
-
Erlwein, Otto, Robinson, Mark J., Kaye, Steve, Wills, Gillian, Izui, Shozo, Wessely, Simon, Weber, Jonathan, Cleare, Anthony, Collier, David, and McClure, Myra O.
- Subjects
- *
COHORT analysis , *PROSTATE cancer , *CHRONIC fatigue syndrome , *CANCER , *PATIENTS , *PROTEINS - Abstract
The novel human gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV), originally described in prostate cancer, has also been implicated in chronic fatigue syndrome (CFS). When later reports failed to confirm the link to CFS, they were often criticised for not using the conditions described in the original study. Here, we revisit our patient cohort to investigate the XMRV status in those patients by means of the original PCR protocol which linked the virus to CFS. In addition, sera from our CFS patients were assayed for the presence of xenotropic virus envelope protein, as well as a serological response to it. The results further strengthen our contention that there is no evidence for an association of XMRV with CFS, at least in the UK. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
30. No Evidence of XMRV or MuLV Sequences in Prostate Cancer, Diffuse Large B-Cell Lymphoma, or the UK Blood Donor Population.
- Author
-
Robinson, Mark James, Tuke, Philip William, Erlwein, Otto, Tettmar, Kate I., Kaye, Steve, Naresh, Kikkeri N., Patel, Anup, Walker, Marjorie M., Kimura, Takahiro, Gopalakrishnan, Ganesh, Tedder, Richard S., and McClure, Myra O.
- Subjects
- *
MOUSE leukemia viruses , *PROSTATE cancer , *B cell lymphoma , *BLOOD donors , *POLYMERASE chain reaction - Abstract
Xenotropic murine leukaemia virus-related virus (XMRV) is a recently described retrovirus which has been claimed to infect humans and cause associated pathology. Initially identified in the US in patients with prostate cancer and subsequently in patients with chronic fatigue syndrome, doubt now exists that XMRV is a human pathogen. We studied the prevalence of genetic sequences of XMRV and related MuLV sequences in human prostate cancer, from B cell lymphoma patients and from UK blood donors. Nucleic acid was extracted from fresh prostate tissue biopsies, formalin-fixed paraffin-embedded (FFPE) prostate tissue and FFPE B-cell lymphoma. The presence of XMRV-specific LTR or MuLV generic gag-like sequences was investigated by nested PCR. To control for mouse DNA contamination, a PCR that detected intracisternal A-type particle (IAP) sequences was included. In addition, DNA and RNA were extracted from whole blood taken from UK blood donors and screened for XMRV sequences by real-time PCR. XMRV or MuLV-like sequences were not amplified from tissue samples. Occasionally MuLV gag and XMRVLTR sequences were amplified from Indian prostate cancer samples, but were always detected in conjunction with contaminating murine genomic DNA. We found no evidence of XMRV or MuLV infection in the UK blood donors. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
31. Mouse DNA contamination in human tissue tested for XMRV.
- Author
-
Robinson, Mark J., Erlwein, Otto W., Kaye, Steve, Weber, Jonathan, Cingoz, Oya, Patel, Anup, Walker, Marjorie M., Wun-Jae Kim, Uiprasertkul, Mongkol, Coffin, John M., and McClure, Myra O.
- Subjects
- *
PROSTATE cancer , *LEUKEMIA , *CHRONIC fatigue syndrome , *CANCER patients - Abstract
Background: We used a PCR-based approach to study the prevalence of genetic sequences related to a gammaretrovirus, xenotropic murine leukemia virus-related virus, XMRV, in human prostate cancer. This virus has been identified in the US in prostate cancer patients and in those with chronic fatigue syndrome. However, with the exception of two patients in Germany, XMRV has not been identified in prostate cancer tissue in Europe. Most putative associations of new or old human retroviruses with diseases have turned out to be due to contamination. We have looked for XMRV sequences in DNA extracted from formalin-fixed paraffin- embedded prostate tissues. To control for contamination, PCR assays to detect either mouse mitochondrial DNA (mtDNA) or intracisternal A particle (IAP) long terminal repeat DNA were run on all samples, owing to their very high copy number in mouse cells. Results: In general agreement with the US prevalence, XMRV-like sequences were found in 4.8% of prostate cancers. However, these were also positive, as were 21.5% of XMRV-negative cases, for IAP sequences, and many, but not all were positive for mtDNA sequences. Conclusions: These results show that contamination with mouse DNA is widespread and detectable by the highly sensitive IAP assay, but not always with less sensitive assays, such as murine mtDNA PCR. This study highlights the ubiquitous presence of mouse DNA in laboratory specimens and offers a means of rigorous validation for future studies of murine retroviruses in human disease. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
32. A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants
- Author
-
Pizzato, Massimo, Erlwein, Otto, Bonsall, David, Kaye, Stephen, Muir, David, and McClure, Myra O.
- Subjects
- *
POLYMERASE chain reaction , *REVERSE transcriptase , *DYES & dyeing , *RETROVIRUSES , *CELL culture , *FLUORESCENT probes , *HIV , *MOUSE leukemia viruses - Abstract
Abstract: PCR-enhanced reverse transcriptase assays (PERT) are sensitive tools for the detection of retroviruses in biological samples. The adaptation of real-time PCR techniques based on fluorescent probes (F-PERT) has added a reliable quantitative capacity to the assay. In the interest of economy and time, the SYBR Green I-based real-time detection system was used to establish a convenient one-step PERT assay (SG-PERT). This assay can be completed in 2h, is linear over six orders of magnitude and can be used to quantify retroviruses belonging to divergent species, such as the human immunodeficiency virus type 1 (HIV-1), murine leukemia virus (MLV) and prototypic foamy virus (PFV). [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
33. Knockdown of mouse VCAM-1 by vector-based siRNA.
- Author
-
Alam, A. K. M. Shamsul, Florey, Oliver, Weber, Michele, Pillai, Radhakrishna G., Chan, Cliburn, Tan, Peng H., Lechler, Robert I., McClure, Myra O., Haskard, Dorian O., and George, Andrew J. T.
- Subjects
- *
GRAFT rejection , *SMALL interfering RNA , *CELL adhesion molecules , *CYTOKINES , *INTERFERONS , *LABORATORY mice - Abstract
Graft rejection is critically dependent on the recruitment of leukocytes via adhesion molecules on the endothelium, and inhibition of these interactions can prolong graft survival. We have therefore developed an approach using siRNA to inhibit the expression of VCAM-I in endothelial cells. We transfected siRNA constructs into murine corneal and vascular endothelium and looked at expression of VCAM-I and other surface molecules by flow cytometry. Adhesion assays (both static and under flow) were used to determine the effect of VCAM-1 inhibition. The activation of cellular stress responses was assessed by RT-PCR. Constructs encoding siRNA can block expression of VCAM-I in both corneal and vascular endothelial cells (in the latter case after cytokine stimulation). Inhibition of VCAM-1 expression reduced the ability of T cells to adhere to endothelium. However, there were non-specific effects of siRNA expression, including upregulation of (Programmed Death Ligand 1) PDLI and decreased cell growth. Analysis of stress pathways showed that the endothelial cells transfected with siRNA had upregulated molecules associated with cell stress. While these data are supportive of a potential therapeutic role for siRNA constructs in blocking the expression of adhesion molecules, they also highlight potential non-specific effects of siRNA that must be carefully considered in any application of this technology. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
34. Comparison of HIV-1 and EIAV-based lentiviral vectors in corneal transduction
- Author
-
Beutelspacher, Sven Christoph, Ardjomand, Navid, Tan, Peng Hong, Patton, Gillian Sarah, Larkin, D. Frank P., George, Andrew J.T., and McClure, Myra O.
- Subjects
- *
CORNEAL sensitivity , *HIV , *HIV infections , *GENES - Abstract
Abstract: In this study we compare the ability of self-inactivating Human Immunodeficiency Virus 1 (HIV-1) and Equine Infectious Anaemia Virus (EIAV)-based vectors to mediate gene transfer to rabbit and human corneas and to a murine corneal endothelial cell line. Both vectors were pseudotyped with vesicular stomatitis virus-G (VSV-G) envelope and contained marker transgenes under the control of an internal CMV promoter. For specificity of action, the heterologous promoter in the EIAV-vector was exchanged for an inducible E-Selectin promoter, previously shown to regulate gene-expression in a plasmid system. We show that EIAV is more efficient than HIV in transducing human and rabbit corneal endothelial cells. Rabbit corneal endothelial cells are transduced in higher quantity than human corneal endothelial cells. In the inducible system, however, we detected impairment between the vector and its internal E-Selectin promoter. Instead of controlled transgene expression or silencing of promoter activity, the U3-modified long-terminal-repeats (LTR) impaired the conditional activity of the E-Selectin promoter. Significant transgene expression was seen without stimulation of the inducible promoter. We show efficient transduction by lentiviruses of a corneal endothelial cell line and of full thickness corneas from different species, confirming that those vectors would be appropriate tools for gene therapy of selected corneal diseases. However, the modification within the U3-LTR did not adequately allow regulated transgene expression. These findings have important implications for vector design for diagnostic or therapeutic opportunities. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
35. Identification of Domains in Gag Important for Prototypic Foamy Virus Egress.
- Author
-
Patton, Gillian S., Morris, Stephen A., Chung, Wayne, Bieniasz, Paul D., and McClure, Myra O.
- Subjects
- *
FOAMY viruses , *VIRUSES , *PROTEINS , *BIOMOLECULES , *MICROORGANISMS - Abstract
Sequence motifs (L domains) have been described in viral structural proteins. Mutations in these lead to a defect at a late stage in virus assembly and budding. For several viruses, recruitment of an endosomal sorting complexes required for transport 1 subunit (Tsg101), a component of the class E vacuolar protein sorting (EVPS) machinery, is a prerequisite for virion budding. To effect this, Tsg101 interacts with the PT/SAP L domain. We have identified candidate L-domain motifs, PSAP, PPPI, and YEIL, in the prototypic foamy virus (PFV) Gag protein, based on their homology to known viral L domains. Mutation of the PSAP and PPPI motifs individually reduced PFV egress, and their combined mutation had an additive effect. When PSAP was mutated, residual infectious PFV release was unaffected by dominant negative Vps4 (an ATPase involved in the final stages of budding), and sensitivity to dominant negative Tsg101 was dramatically reduced, suggesting that the PSAP motif functions as a conventional class E VPS-dependent L domain. Consistent with this notion, yeast two-hybrid analysis showed a PSAP motif-dependent interaction between PFV Gag and Tsg101. Surprisingly, PFV release which is dependent on the PPPI motif was Vps4-independent and was partially inhibited by dominant negative Tsg101, suggesting that PPPI functions by an unconventional mechanism to facilitate PFV egress. Mutation of the YEIL sequence completely abolished particle formation and also reduced the rate of Gag processing by the viral protease, suggesting that the integrity of YEIL is required at an assembly step prior to budding and YEIL is not acting as an L domain. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
36. Immunolipoplexes: An Efficient, Nonviral Alternative for Transfection of Human Dendritic Cells with Potential for Clinical Vaccination
- Author
-
Tan, Peng H., Beutelspacher, Sven C., Wang, Yao-He, McClure, Myra O., Ritter, Mary A., Lombardi, Giovanna, and George, Andrew J.T.
- Subjects
- *
DENDRITIC cells , *MONOCYTES , *CYTOKINES , *VACCINATION - Abstract
Abstract: Genetic manipulation of dendritic cells (DCs) is important in the context of using either mature DCs to immunize patients or immature DCs to induce tolerance. Here, we describe a novel method of transfecting monocyte-derived human DCs using immunolipoplexes containing anti-CD71 or anti-CD205 monoclonal Abs. This results in up to 20% transfection, which can be increased to 20–30% if the immunolipoplexes are used to transfect CD14+ monocytes prior to differentiation into DCs. Transfected DCs can be substantially enriched using a drug-selection protocol during differentiation. Unlike adenoviral transduction, this nonviral transfection does not alter the expression of costimulatory molecules or the production of proinflammatory cytokines by DCs. In addition, DC function is unaltered, as assessed by mixed lymphocyte reactions. To test the feasibility of the immunolipoplexes and selection protocol for therapeutic intervention, we transfected DCs with the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO). Allogeneic T cells exposed to IDO-expressing DCs did not proliferate, secreted more IL-10 and less Th1 and Th2 cytokines, and had a higher amount of apoptosis than T cells incubated with control DCs. Furthermore the remaining T cells were rendered anergic to further stimulation by allogeneic DC. These immunolipoplexes, which can be easily and rapidly assembled, have potential for clinical immunization, in particular for tolerance induction protocols. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
37. Testing for responses to the wrong SARS-CoV-2 antigen?
- Author
-
Rosadas, Carolina, Randell, Paul, Khan, Maryam, McClure, Myra O, and Tedder, Richard S
- Subjects
- *
ANTIGENS - Published
- 2020
- Full Text
- View/download PDF
38. No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys.
- Author
-
Patience, Clive, Patton, Gillian S., Takeuchi, Yasuhiro, Weiss, Robin A., McClure, Myra O., Rydberg, Lennart, and Breimer, Michael E.
- Subjects
- *
RETROVIRUS diseases , *XENOGRAFTS , *COMPLICATIONS from organ transplantation , *IMMUNOLOGY - Abstract
Presents research which studied patients exposed to or treated with living porcine cells or tissues for evidence of pig endogenous retrovirus (PERV) infection. Potential value of xenotransplantation; Possible hazards of xenotransplantation; Methods; Findings; Absence of porcine cells in patients studied; No detection of PERV; Applications for research.
- Published
- 1998
- Full Text
- View/download PDF
39. Review of uptake of interventions to reduce mother to child transmission of HIV by women...
- Author
-
Lyall, E.G. Hermione, Stainsby, Christopher, Taylor, Graham P., Ait-Khaled, Mounir, Bingham, Samantha, Evans, Jennifer A., Wright, Anne, Weber, Jonathan N., McClure, Myra O., Walters, Sam, and Tudor-Williams, Gareth
- Subjects
- *
HIV infection transmission , *PRENATAL diagnosis - Abstract
Presents a study which examined the change in uptake of interventions to reduce transmission of human immunodeficiency virus (HIV) from mothers to infants from January 1994 to July 1997 in central London, England. Review of mother-infant pairs presented for infant diagnosis of HIV infection; Interventions examined; Results obtained.
- Published
- 1998
- Full Text
- View/download PDF
40. Correction: Sera selected from national STI surveillance system shows Chlamydia trachomatis PgP3 antibody correlates with time since infection and number of previous infections.
- Author
-
Blomquist, Paula B., Migchelsen, Stephanie J., Wills, Gillian, McClure, Eleanor, Ades, Anthony E., Kounali, Daphne, Dunbar, J. Kevin, McClure, Myra O., Soldan, Kate, Woodhall, Sarah C., and Horner, Patrick
- Subjects
- *
CHLAMYDIA trachomatis , *IMMUNOGLOBULINS , *INFECTION , *SERUM - Published
- 2019
- Full Text
- View/download PDF
41. CORRESPONDENCE.
- Author
-
Frater, John, Dunn, David, Weber, Jonathan N., McClure, Myra O., Perno, Carlo-Federico, Cozzi-Lepri, Alessandro, Balotta, Claudia, and Monforte, Antonella d'Arminio
- Subjects
- *
HIV , *MICROBIAL mutation - Abstract
Comments on a study on the association between secondary mutations in human immunodeficiency virus Type 1 protease and therapeutic outcome. Virologic and immunologic responses; Sequencing of virus isolates.
- Published
- 2002
42. XMRV infection in human diseases.
- Author
-
Erlwein, Otto, Robinson, Mark J., Kaye, Steve, McClure, Myra O., Walker, Marjorie M., Patel, Anup, Wun-Jae Kim, Uiprasertkul, Mongkol, Gopalakrishnan, Ganesh, Kimura, Takahiro, and Naresh, Kikkeri
- Subjects
- *
DISEASES - Abstract
An abstract of the paper "XMRV Infection in Human Diseases," by Otto Erlwein and colleagues that was presented at the 15th International Conference on Human Retroviruses: HTLV and Related Viruses in Leuven and Gembloux, Belgium from June 5-8, 2011 is presented.
- Published
- 2011
- Full Text
- View/download PDF
43. Foamy Virus Bet Proteins Function as Novel Inhibitors of the APOBEC3 Family of Innate Antiretroviral Defense Factors.
- Author
-
Russell, Rebecca A., Wiegand, Heather L., Moore, Michael D., Schäfer, Alexandra, McClure, Myra O., and Cullen, Bryan R.
- Subjects
- *
FOAMY viruses , *RETROVIRUSES , *INFECTION , *PRIMATES , *PROTEINS - Abstract
Foamy viruses are a family of complex retroviruses that establish common, productive infections in a wide range of nonhuman primates. In contrast, humans appear nonpermissive for foamy virus replication, although zoonotic infections do occur. Here we have analyzed the ability of primate and mouse APOBEC3G proteins to inhibit the infectivity of primate foamy virus (PFV) virions produced in their presence. We demonstrate that several APOBEC3 proteins can potently inhibit the infectivity of a PFV-based viral vector. This inhibition correlated with the packaging of inhibitory APOBEC3 proteins into PFV virions, due to a specific PFV Gag/APOBEC3 interaction, and resulted in the G to A hypermutation of PFV reverse transcripts. While inhibition of PFV virion infectivity by primate APOBEC3 proteins was largely relieved by coexpression of the PFV Bet protein, a cytoplasmic auxiliary protein of previously uncertain function, Bet failed to relieve inhibition caused by murine APOBEC3. PFV Bet bound to human, but not mouse, APOBEC3 proteins in coexpressing cells, and this binding correlated with the specific inhibition of their incorporation into PFV virions. Of note, both PFV Bet and a second Bet protein, derived from an African green monkey foamy virus, rescued the infectivity of Vif-deficient human immunodeficiency virus type 1 (HIV-1) virions produced in the presence of African green monkey APOBEC3G and blocked the incorporation of this host factor into HIV-1 virion particles. However, neither foamy virus Bet protein reduced APOBEC3 protein expression levels in virion producer cells. While these data identify the foamy virus Bet protein as a functional ortholog of the HIV-1 Vif auxiliary protein, they also indicate that Vif and Bet block APOBEC3 protein function by distinct mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.